seri
n
phosphonoalkyl
uracil
prepar
twostep
reaction
sequenc
xaminoalkylphosphon
e
isocyan
follow
uracil
ring
closur
standard
condit
nc
nb
n
phosphonoalkyl
uracil
transform
respect
deriv
later
benzoyl
compound
evalu
vitro
activ
broad
varieti
dna
rna
virus
one
compound
slightli
activ
human
cytomegaloviru
hel
cell
cultur
ec
lm
anoth
show
weak
activ
varicellazost
viru
tk
vzv
strain
oka
tk
vzv
strain
ec
lm
respect
addit
sever
compound
exhibit
notic
inhibitori
effect
prolifer
human
cervic
carcinoma
cell
hela
concentr
lower
lm
graphic
abstract
acycl
nucleosid
nucleotid
analogu
use
clinic
practic
almost
year
becom
cornerston
treatment
patient
viral
infect
nucleosid
analogu
acyclovir
ganciclovir
penciclovir
well
acycl
nucleosid
phosphon
anp
name
adefovir
cidofovir
tenofovir
belong
wide
use
antivir
drug
fig
ribos
moieti
natur
nucleosid
nucleotid
replac
linear
branch
aliphat
unit
obtain
analogu
specif
activ
follow
activ
viral
andor
cellular
kinas
antivir
activ
compound
reli
enzym
inhibit
incorpor
activ
metabolit
viral
nucleic
acid
result
inhibit
viral
genom
replic
last
decad
sever
new
drug
includ
nucleosid
nucleotid
analogu
approv
treatment
viral
infect
cancer
chemotherapi
mani
nucleosidenucleotid
analogu
deriv
current
preclin
clinic
trial
demonstr
rapidli
area
research
grow
howev
analogu
poor
oral
bioavail
associ
toxic
limit
applic
treatment
cancer
viral
infect
moreov
longterm
treatment
antivir
drug
may
result
lower
sensit
virus
chemotherapeut
drug
resist
reason
search
new
compound
higher
antivir
antitumor
activ
good
bioavail
better
solubl
proper
balanc
efficaci
longterm
toxic
still
continu
known
synthet
strategi
anp
commonli
appli
alkyl
heterocycl
base
construct
nucleobas
skeleton
appropri
termin
primari
amin
less
frequent
use
herein
report
effici
synthesi
biolog
evalu
new
seri
acycl
nucleotid
analogu
applic
latter
approach
scheme
xaminoalkylphosphon
prepar
sever
method
arbuzov
reaction
n
xbromoalkyl
phthalimid
trialkyl
phosphit
seem
frequent
appli
altern
xaminoalkylphosphon
synthes
nitril
xazidophosphon
employ
hydrogenolysi
diethyl
aminoalkylphosphon
aminomethyl
use
studi
known
alreadi
describ
literatur
thu
diethyl
aminomethylphosphon
prepar
total
yield
n
bromomethyl
phthalimid
follow
treatment
hydrazin
wherea
xaminoalkylphosphon
synthes
correspond
xazidoalkylphosphon
catalyt
hydrogen
howev
sever
literatur
report
notic
format
signific
amount
symmetr
secondari
amin
byproduct
hydrogenolysi
azid
depend
azid
concentr
azid
catalyst
ratio
xazidophosphon
subject
hydrogen
presenc
pdc
symmetr
secondari
amin
contamin
major
phosphon
judg
p
nmr
spectra
scheme
mixtur
xaminoalkylphosphon
contain
variou
amount
symmetr
secondari
amin
separ
silica
gel
column
alkyl
nucleobas
substitut
alkylphosphon
gener
recogn
caprici
process
sinc
dealkyl
phosphon
ester
accompani
format
carbonnucleobas
bond
primari
reason
replac
odimethyl
odiethyl
ester
odiisopropyl
phosphon
base
experi
group
conclud
altern
approach
independ
construct
pyrimidin
ring
function
xaminoalkylphosphon
feasibl
alkyl
n
phosphonoalkyl
uracil
synthes
xaminoalkylphosphon
twostep
procedur
involv
reaction
e
isocyan
situ
gener
e
chlorid
silver
cyanat
follow
uracil
ring
closur
presenc
h
scheme
convers
uracil
phosphon
achiev
treatment
nchlorosuccinimid
nc
nbromosuccinimid
nb
respect
reagent
condit
h
pdc
etoh
rt
h
wherea
synthes
use
iodin
cerium
iv
ammonium
nitrat
scheme
although
iodin
bromin
uracil
proceed
regioselect
chlorin
uracil
phosphon
appli
condit
provid
mixtur
regioisom
approxim
ratio
moreov
base
literatur
report
previou
observ
regard
effect
benzoyl
substitu
nucleobas
antivir
activ
n
benzoyluracil
analogu
synthes
phosphon
shown
scheme
structur
puriti
synthes
compound
establish
h
p
c
nmr
ir
techniqu
well
element
analysi
synthes
compound
evalu
antivir
activ
wide
varieti
dna
rna
virus
use
follow
cell
hippeastrum
hybrid
agglutinin
hha
urtica
dioica
agglutinin
uda
dextran
sulfat
molecular
weight
ribavirin
oseltamivir
carboxyl
amantadin
rimantadin
use
refer
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusplaqu
format
vzv
virusinduc
cytopathogen
virus
found
acycl
phosphon
analogu
contain
n
group
modifi
nucleobas
exhibit
notic
activ
thu
compound
show
activ
cytomegaloviru
strain
human
embryon
lung
hel
cell
ec
lm
wherea
compound
prove
activ
vzv
tk
strain
oka
tkstrain
ec
lm
respect
antivir
activ
compound
vzv
tkstrain
appear
slightli
better
activ
acyclovir
brivudin
use
refer
compound
ec
lm
respect
ration
observ
activ
n
deriv
one
refer
easier
transport
cell
membran
comparison
precursor
appear
inact
enter
cell
debenzoyl
would
provid
nucleosid
analogu
capabl
watsoncrick
ba
pair
previou
result
support
conclus
cytotox
test
compound
toward
uninfect
host
cell
defin
minimum
cytotox
concentr
mcc
caus
microscop
detect
alter
normal
cell
morpholog
cytotox
concentr
cc
caus
decreas
cell
viabil
determin
use
colorimetr
mt
assay
system
none
test
compound
affect
cell
morpholog
hel
hela
vero
mdck
crfk
cell
mcc
cc
compound
concentr
lm
cytostat
activ
test
compound
defin
inhibitori
concentr
ic
compound
concentr
caus
decreas
cell
prolifer
ic
valu
determin
murin
leukemia
cell
human
lymphocyt
cem
cell
human
cervic
carcinoma
hela
cell
sever
synthes
compound
show
margin
inhibitori
effect
prolifer
hela
cell
concentr
lower
lm
tabl
seri
n
phosphonoalkyl
uracil
effici
obtain
xaminoalkylphosphon
twostep
process
involv
reaction
e
isocyan
follow
uracil
ring
closur
uracil
phosphon
success
transform
well
n
benzoyluracil
synthes
compound
test
vitro
antivir
activ
broad
varieti
dna
rna
virus
compound
slightli
activ
human
cytomegaloviru
hel
cell
cultur
ec
lm
show
activ
tk
tkvzv
strain
ec
valu
lm
oka
strain
lm
strain
two
threefold
better
potenc
acyclovir
brivudin
ec
lm
respect
among
sever
compound
exhibit
poor
inhibitori
effect
prolifer
human
cervic
carcinoma
cell
hela
concentr
lower
lm
contrast
none
compound
affect
prolifer
cem
cell
cell
concentr
lm
experiment
h
nmr
taken
cdcl
follow
spectromet
varian
bruker
avanc
iii
mhz
tm
intern
standard
chemic
shift
ppm
respect
tm
coupl
constant
j
hz
c
nmr
spectra
record
cdcl
solut
varian
bruker
avanc
iii
mhz
spectromet
mhz
respect
p
nmr
spectra
taken
cdcl
varian
bruker
avanc
iii
mhz
spectromet
mhz
respect
ir
spectra
measur
infin
ftir
spectromet
kbr
pellet
film
absorpt
given
cm
melt
point
determin
boetiu
apparatu
element
analys
perform
microanalyt
laboratori
faculti
perkin
elmer
pe
chn
analyz
result
found
good
agreement
calcul
valu
follow
adsorb
use
column
chromatographi
merck
silica
gel
mesh
analyt
tlc
merck
tlc
plastic
sheet
silica
gel
f
appli
reagent
silver
cyanat
alfa
aesar
catalogu
number
tokyo
chemic
industri
tci
catalogu
number
inorgan
reagent
commerci
avail
use
receiv
solvent
dri
accord
literatur
method
e
chlorid
obtain
accord
known
protocol
diethyl
aminomethylphosphon
prepar
accord
literatur
colorless
oil
yield
gener
procedur
prepar
aminoalkylphosphon
xazidoalkylphosphon
mmol
dissolv
cm
ethanol
pdc
mg
gener
procedur
prepar
acryloylurea
solut
g
chlorid
mmol
cm
dri
toluen
reflux
argon
atmospher
g
silver
cyanat
mmol
previous
dri
vacuo
h
protect
light
min
mixtur
allow
cool
transfer
via
cannula
solut
respect
xaminoalkylphosphon
mmol
cm
dri
dmf
solid
agcl
wash
dri
toluen
cm
remov
residu
isocyan
ad
reaction
flask
reaction
mixtur
stir
room
temperatur
overnight
solid
residu
filter
layer
celit
solvent
evapor
crude
product
chromatograph
silica
gel
column
chloroformmethanol
mixtur
vv
afford
phosphon
gener
procedur
prepar
uracil
deriv
solut
respect
acryloylurea
mmol
cm
dioxan
cm
h
ad
mixtur
reflux
h
naoh
ad
reach
ph
reaction
mixtur
concentr
dryness
solid
residu
chloroform
ad
mixtur
stir
min
filter
layer
celit
concentr
product
purifi
column
chromatographi
chloroformmethanol
mixtur
vv
give
pure
uracil
deriv
diethyl
hz
dd
j
hz
dq
j
hz
poch
ch
j
hz
ch
p
j
hz
poch
ch
ppm
colorless
oil
yield
colorless
oil
yield
colorless
oil
yield
solut
respect
phosphon
mmol
cm
pyridin
nhalogenosuccinimid
nc
nb
mmol
ad
mixtur
stir
min
satur
aqueou
nahco
solut
cm
ad
mixtur
extract
chloroform
cm
combin
organ
phase
dri
mgso
filter
solvent
remov
crude
product
purifi
column
chromatographi
crystal
diethyl
viru
ccid
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
vzv
presenc
vari
concentr
test
compound
viral
cytopath
plaqu
format
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopathogen
viral
plaqu
format
methodolog
antihiv
assay
follow
human
cem
cellscm
cell
infect
hiv
iiib
rod
cm
seed
mm
well
microtit
plate
contain
appropri
dilut
test
compound
day
incub
hivinduc
cem
giant
cell
format
examin
microscop
assay
perform
microtit
plate
well
ad
tumor
cell
given
amount
test
compound
cell
allow
prolifer
h
murin
leukemia
cell
h
human
lymphocyt
cem
human
cervix
carcinoma
hela
cell
humidifi
co
control
atmospher
end
incub
period
cell
count
coulter
counter
ic
inhibitori
concentr
defin
concentr
compound
inhibit
cell
prolifer
